NASDAQ · STTK
Shattuck Labs, Inc.
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
Loading market information…
NASDAQ · TIL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Instil Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Instil Bio, Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$0.17. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Instil Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 4, 2025 |
| -$1.82+51.47% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$3.54-70.19% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.72-$0.09 (-1.46%)
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
$1.72-$0.02 (-0.87%)
InflaRx N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.86% below the high.
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
$3.30-$0.16 (-4.62%)
Whitehawk Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$1.99-$0.07 (-3.4%)
Zentalis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.37% below the high.
$0.86-$0.03 (-3.35%)
Pliant Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.75% below the high.
$0.43-$0.01 (-3.15%)
Oncolytics Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.1% below the high.
